Biogen Dividends and Buybacks

Dividend criteria checks 0/6

Biogen does not have a record of paying a dividend.

Key information

n/a

Dividend yield

0%

Buyback Yield

Total Shareholder Yield0%
Future Dividend Yield0%
Dividend Growthn/a
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Payout ration/a

Recent dividend and buyback updates

No updates

Recent updates

Market Cool On Biogen Inc.'s (NASDAQ:BIIB) Earnings

Dec 24
Market Cool On Biogen Inc.'s (NASDAQ:BIIB) Earnings

Biogen Q3 Earnings Review: Why I Remain Optimistic Despite Difficult Quarter

Oct 31

Does Biogen (NASDAQ:BIIB) Have A Healthy Balance Sheet?

Oct 01
Does Biogen (NASDAQ:BIIB) Have A Healthy Balance Sheet?

What You Can Learn From Biogen Inc.'s (NASDAQ:BIIB) P/E

Sep 04
What You Can Learn From Biogen Inc.'s (NASDAQ:BIIB) P/E

Biogen: Q2 Earnings, Share Price May Have Bottomed Out As CEO Makes Mark

Aug 17

Biogen Stock: Cheapish, But With Few Growth Prospects

Jul 11

Is Biogen (NASDAQ:BIIB) Using Too Much Debt?

May 23
Is Biogen (NASDAQ:BIIB) Using Too Much Debt?

Biogen's Revenue Dip Meets Cost Cuts In Q1 (Rating Upgrade)

Apr 29

Earnings Update: Biogen Inc. (NASDAQ:BIIB) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts

Apr 28
Earnings Update: Biogen Inc. (NASDAQ:BIIB) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts

The Price Is Right For Biogen Inc. (NASDAQ:BIIB)

Apr 15
The Price Is Right For Biogen Inc. (NASDAQ:BIIB)

We Think You Can Look Beyond Biogen's (NASDAQ:BIIB) Lackluster Earnings

Feb 21
We Think You Can Look Beyond Biogen's (NASDAQ:BIIB) Lackluster Earnings

Biogen Inc. Just Missed EPS By 21%: Here's What Analysts Think Will Happen Next

Feb 16
Biogen Inc. Just Missed EPS By 21%: Here's What Analysts Think Will Happen Next

Biogen's Q4 Earnings Disappoint Amidst Strategic Challenges (Rating Downgrade)

Feb 14

Here's Why Biogen (NASDAQ:BIIB) Can Manage Its Debt Responsibly

Jan 31
Here's Why Biogen (NASDAQ:BIIB) Can Manage Its Debt Responsibly

Biotech And Pharma Diversification Pays Off

Jan 25

Getting In Cheap On Biogen Inc. (NASDAQ:BIIB) Might Be Difficult

Dec 26
Getting In Cheap On Biogen Inc. (NASDAQ:BIIB) Might Be Difficult

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if BIIB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BIIB's dividend payments have been increasing.


Dividend Yield vs Market

Biogen Dividend Yield vs Market
How does BIIB dividend yield compare to the market?
SegmentDividend Yield
Company (BIIB)n/a
Market Bottom 25% (US)1.4%
Market Top 25% (US)4.5%
Industry Average (Biotechs)2.4%
Analyst forecast (BIIB) (up to 3 years)0%

Notable Dividend: Unable to evaluate BIIB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BIIB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate BIIB's payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as BIIB has not reported any payouts.


Discover strong dividend paying companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 08:25
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Biogen Inc. is covered by 74 analysts. 32 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
Steven ChesneyAtlantic Equities LLP
Brian SkorneyBaird